Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab

Introduction Conventional first-line therapy for squamous cell carcinoma of anal canal is definitive chemoradiotherapy with a curative intent. Due to the efficacy of treatment for locoregional disease and rarity of metastatic anal carcinoma, clinical trial data for treatment of metastatic disease is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2020-06, Vol.26 (4), p.1025-1028
Main Authors: Lerner, Jaren, Michel, Miguel, Dasanu, Constantin A
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Conventional first-line therapy for squamous cell carcinoma of anal canal is definitive chemoradiotherapy with a curative intent. Due to the efficacy of treatment for locoregional disease and rarity of metastatic anal carcinoma, clinical trial data for treatment of metastatic disease is lacking. Case report Herein, we describe a patient with relapsed, metastatic squamous cell carcinoma of the anal canal treated with cetuximab as the third-line therapy. Management and outcome: The patient responded to this pharmacological agent, meeting the definition of a partial response per response evaluation criteria in solid tumors (RECIST). Discussion EGFR inhibitors are potential avenues for the subsequent lines of therapy in metastatic or relapsed/refractory anal cancer. Prospective clinical trials of cetuximab alone or in combination with other agents are warranted in this setting in the future.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155219884605